Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Q1 2019/20 Earnings Presentation
8 slides from Coloplast A/s Class B's earnings presentation, Feb 6, 2020
Slide 1: Making it easier to get back on track
Making it easier to get back on track It took a while but now I have taken back control. I’m trying new things, pushing my limits again. Alessia Leading intimate Coloplast Earnings healthcare Conference Call Q1 2019/20 February Roadshow 6th,presentation 2020 Q1 2019/20 Making life easier Ostomy Care
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Solid start to the year with 8% organic growth in Q1 and guidance for 2019/20 maintained
Solid start to the year with 8% organic growth in Q1 and guidance for 2019/20 maintained Revenue growth Q1 2019/20 Highlights • Organic growth of 8% (9% reported growth in DKK) driven by solid Reported revenue (DKKm) +8% momentum across all business areas and geographies Organic growth • Solid quart
Slide 4: Solid growth across all business areas and geographical regions
Solid growth across all business areas and geographical regions Q1 19/20 revenue by business area Q1 19/20 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Share of organic area DKKm growth area DKKm growth Ostomy Care 1,907 9%
Slide 5: Q1 2019/20 reported revenue grew 9% driven by solid organic growth of 8%
Q1 2019/20 reported revenue grew 9% driven by solid organic growth of 8% Comments Revenue development • Q1 2019/20 reported revenue increased by DKK 391m (DKKm) or 9% compared to Q1 2018/19 46 4,712 • The majority of growth was driven by organic growth 345 contributing DKK 345m or 8% to reported rev
Slide 6: EBIT grew 13% in Q1 2019/20
EBIT grew 13% in Q1 2019/20 Comments EBIT margin development (%) • Gross margin of 68% in DKK compared to 67% last year 0.6 0.0 31.2 • Positive impact from operating leverage driven by revenue growth, ongoing efficiency improvements, GOP4 and the closure of the 1.0 Thisted factory in June 2019 0.6 •
Slide 7: Unchanged guidance for FY 2019/20
Unchanged guidance for FY 2019/20 Guidance 2019/20 Guidance 2019/20 (DKK)* Key assumptions • Stable growth trends across regions and business areas • Up to 1% negative price pressure from reforms in France, Holland and Switzerland Sales growth 7-8% 7-8% • Approx. half of 9% price cut in Chronic Care
Slide 8: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast Group - Ostomy Care /